A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

Persistent Asthma Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02040779
• Other study ID #: BDB-AS-304
• Status: Completed
• Phase: Phase 3
• Start date: December 26, 2013
• Est. completion date: December 24, 2014

Study information

• Verified date: November 2021
• Source: Teva Branded Pharmaceutical Products R&D, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled parallel-group study. Participants will be randomly assigned to receive treatment with beclomethasone dipropionate at a dosage of 80 or 160 mcg/day delivered via a Breath-Actuated Inhaler (BAI); or a matching BAI placebo, in a 1:1:1 ratio after a 14- to 21-day run-in period. Participants and investigators will remain blinded to randomized treatment assignment during the study

Recruitment information / eligibility

• Status: Completed
• Enrollment: 273
• Est. completion date: December 24, 2014
• Est. primary completion date: December 24, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Severity of Disease: The patient has persistent asthma, with an forced expiratory volume in 1 second (FEV1) 40%-85% of the value predicted for age, height, sex, and race as per the National Health and Nutrition Examination Survey (NHANES III) reference values at screening visit (SV) (Hankinson et al 1999).

• Current asthma therapy: The patient is currently being treated with 1 of the following:

1) inhaled corticosteroids (ICSs) at a stable daily dose of less than or equal to 220 mcg/day fluticasone propionate via metered dose inhaler (MDI) or equivalent for a minimum of 4 weeks (28 days) before screening visit, or 2) a stable daily dosage of non-corticosteroid therapy, including leukotriene modifiers, theophylline, chromones, or short-acting beta-2 agonists (SABAs) alone or in combination for a minimum of 4 weeks (28 days) before screening visit (SV).

• Reversibility of disease: The patient has demonstrated at least 15% and at least 200 mL increase from baseline FEV1 (patients age 18 and older) within 30 minutes after 2-4 inhalations of albuterol/salbutamol hydrofluoroalkane (HFA) MDI (90 mcg ex-actuator) or equivalent at SV or on retesting. - Other criteria apply, please contact the investigator for more information

Exclusion Criteria:

• The patient has a history of life-threatening asthma, defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest, or hypoxic seizures.

• The patient is a pregnant or lactating female or plans to become pregnant.

• The patient has a known hypersensitivity to any corticosteroid or any of the excipients in the study drug or rescue medication formulation.

• The patient currently smokes or has a smoking history of 10 pack-years or more (a pack-year is defined as smoking 1 pack of cigarettes/day for 1 year). The patient may not have used tobacco products within the past year.

• The patient has had an asthma exacerbation requiring oral corticosteroids within 1 month before SV, or has had any hospitalization for asthma within 2 months before SV.

• The patient has historical or current evidence of a clinically significant disease. Significant disease is defined as any disease that in the medical judgment of the investigator would put the safety of the patient at risk through participation or that could affect the efficacy or safety analysis if the disease/condition worsened during the study.

• Other criteria apply, please contact the investigator for more information

Related Conditions & MeSH terms

• Asthma
• Persistent Asthma

Intervention

Drug:
• Beclomethasone dipropionate breath-actuated inhaler
Beclomethasone dipropionate (BDP) breath-actuated inhaler (BAI) given in dosages of either 40 mcg/inhalation or 80 mcg/inhalation. Study drug was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
• Placebo breath-actuated inhaler
Placebo was provided in matching breath-actuated inhaler (BAI) devices. The placebo devices were identical to the devices used to deliver active drug. Placebo was administered twice each day, in the morning and in the evening, after the completion of the asthma symptom score and the PEF measurements, in that order.
• albuterol/salbutamol
Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period

Locations

Country	Name	City	State
United States	Teva Investigational Site 10969	Austin	Texas
United States	Teva Investigational Site 10954	Baltimore	Maryland
United States	Teva Investigational Site 10942	Bellevue	Nebraska
United States	Teva Investigational Site 12940	Bethesda	Maryland
United States	Teva Investigational Site 12812	Boerne	Texas
United States	Teva Investigational Site 10972	Bozeman	Montana
United States	Teva Investigational Site 10948	Centennial	Colorado
United States	Teva Investigational Site 10958	Centennial	Colorado
United States	Teva Investigational Site 12810	Cincinnati	Ohio
United States	Teva Investigational Site 10957	Colorado Springs	Colorado
United States	Teva Investigational Site 10970	Columbia	Missouri
United States	Teva Investigational Site 10949	Dallas	Texas
United States	Teva Investigational Site 10953	El Paso	Texas
United States	Teva Investigational Site 10964	Greenfield	Wisconsin
United States	Teva Investigational Site 12807	Houston	Texas
United States	Teva Investigational Site 12813	Huntington Beach	California
United States	Teva Investigational Site 10947	Indianapolis	Indiana
United States	Teva Investigational Site 10943	Iowa City	Iowa
United States	Teva Investigational Site 12811	Knoxville	Tennessee
United States	Teva Investigational Site 10940	Lake Oswego	Oregon
United States	Teva Investigational Site 10952	Medford	Oregon
United States	Teva Investigational Site 10941	Minneapolis	Minnesota
United States	Teva Investigational Site 10944	Mission Viejo	California
United States	Teva Investigational Site 12941	Missoula	Montana
United States	Teva Investigational Site 10950	New Braunfels	Texas
United States	Teva Investigational Site 10955	North Dartmouth	Massachusetts
United States	Teva Investigational Site 12805	Oklahoma City	Oklahoma
United States	Teva Investigational Site 12942	Oklahoma City	Oklahoma
United States	Teva Investigational Site 10946	Orange	California
United States	Teva Investigational Site 12806	Orangeburg	South Carolina
United States	Teva Investigational Site 12939	Pittsburgh	Pennsylvania
United States	Teva Investigational Site 10956	Portland	Oregon
United States	Teva Investigational Site 10945	Raleigh	North Carolina
United States	Teva Investigational Site 10968	Rolla	Missouri
United States	Teva Investigational Site 10963	Rolling Hills Estates	California
United States	Teva Investigational Site 10961	San Antonio	Texas
United States	Teva Investigational Site 10960	San Diego	California
United States	Teva Investigational Site 10973	San Diego	California
United States	Teva Investigational Site 10975	San Jose	California
United States	Teva Investigational Site 12814	Sarasota	Florida
United States	Teva Investigational Site 12809	Savannah	Georgia
United States	Teva Investigational Site 10967	Seattle	Washington
United States	Teva Investigational Site 10959	Skillman	New Jersey
United States	Teva Investigational Site 10974	Sylvania	Ohio
United States	Teva Investigational Site 10962	Tallahassee	Florida
United States	Teva Investigational Site 10951	Tulsa	Oklahoma
United States	Teva Investigational Site 12808	Waco	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Teva Branded Pharmaceutical Products R&D, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Standardized Baseline-Adjusted Trough Morning Forced Expiratory Volume in One Minute (FEV1) Area Under the Effect Curve From Time Zero to 12 Weeks (AUEC(0-12wk)) by Actual Treatment Received	The primary efficacy variable was the standardized baseline-adjusted trough morning (pre-dose and pre-rescue bronchodilator) FEV1 AUEC(0-12wk). Pulmonary function measurements such as FEV1 were obtained electronically by spirometry at the randomization visit (Day 1), each treatment visit (Weeks 2, 4, 8 and 12) and any unscheduled visit (such as the early termination visit). This summary is based on observed values recorded as 'best attempt'.; The least-square (LS) means, difference of LS means and its 95% confidence interval (CI), and p-value represent the results obtained from the analysis of covariance with covariate adjustment for baseline, sex, age, current asthma therapy, and treatment.	Baseline (Day 1 predose), weeks 2, 4, 8 and 12
Secondary	Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Rate Over the 12-Week Treatment Period	Change from baseline in the weekly average of daily trough morning (pre-dose and pre-rescue bronchodilator) PEF by handheld spirometer over the 12-week treatment period.; PEF were determined twice daily, in the morning and in the evening, before administration of study drug or rescue medications. A handheld spirometer was provided to patients and used to determine the morning and evening PEF throughout the study. The spirometer was programmed to record the highest PEF obtained from 3 valid attempts.; Baseline was defined as the average of recorded trough morning PEF assessments over the 7 days prior to the first dose of double-blind study treatment, including the morning assessment at the randomization visit.; The LS means, difference of LS means and its 95% confidence interval, and p value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asthma therapy, treatment, week, and treatment by week interaction.	Baseline (Days -6 to Day 1 pre-dose), daily up to Week 12
Secondary	Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-Week Treatment Period	A hand-held peak flow meter was provided to patients at the screening visit and used to determine the morning and evening PEF throughout the course of the study. The patient recorded the highest value of 3 measurements obtained in the morning and evening in the patient diary.; Baseline in evening PEF is defined as the average of recorded evening PEF assessments over the 7-day window before randomization.; The LS means, difference of LS means and its 95% confidence interval, and p value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asthma therapy, treatment, week, and treatment by week interaction.	Baseline (Days -6 to Day 1 pre-dose), daily up to Week 12
Secondary	Change From Baseline in Weekly Average of Total Daily Use of Albuterol/Salbutamol Inhalation Aerosol Over Weeks 1-12	Change from baseline in the use of rescue medication, albuterol/salbutamol, during the treatment period offers an indication of asthma control.; The LS means, difference of LS means and its 95% CI, and p-value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asthma therapy, treatment, week and treatment by week interaction.; Baseline was defined as the average of recorded daily usage of albuterol/salbutamol inhalation aerosol over the 7 days prior to the first dose of double-blind study treatment, including morning usage at the randomization visit.	Baseline (Days -6 to Day 1 pre-dose), daily up to Week 12
Secondary	Change From Baseline in Weekly Average of Total Daily Asthma Symptom Score Over the 12-Week Treatment Period	Asthma symptom scores were recorded in the patient's diary each morning and evening before determining FEV1 and PEF and before administration of study or rescue medications.; The Daytime Symptom Score was recorded in the evening on a scale of 0 (No symptoms during the day) to 5 (Symptoms so severe that I could not go to work or perform normal daily activities) plus the Nighttime Symptom Score in the morning on a scale of 0 (No symptoms during the night) to 4 (Symptoms so severe that I did not sleep at all) for a total score range of 0-9.; Baseline was defined as the average of recorded daily asthma symptom scores (average of daytime and nighttime score) over the 7 days prior to the first dose of study treatment, including the morning assessment at the randomization visit.; The LS means, difference of LS means and its 95% CI, and p value are obtained from the mixed model for repeated measures analysis with covariate adjustment for baseline, sex, age, current asthma therapy,	Baseline (Days -6 to Day 1 pre-dose), daily up to Week 12
Secondary	Kaplan-Meier Estimates of Time to Study Drug Treatment Withdrawal Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period	The time to patient study drug treatment withdrawal due to worsening asthma was defined as the number of days elapsed from the date of randomization to the date of withdrawal due to meeting stopping criteria. Alert criteria for individual patients with worsening asthma were designed to ensure patient safety. The investigator determined whether the patient's overall clinical picture is consistent with worsening asthma and if the patient should be withdrawn from study drug treatment (but not the study) and be placed on appropriate asthma therapy in the interest of patient safety.; An example of alert criteria is: FEV1 as measured at the study center is below the FEV1 stability limit value calculated at randomization visit (Day 1).; Other criteria as defined in the protocol.	Treatment period: daily from Day 1 up to Week 12
Secondary	Number of Participants Withdrawn From Study Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period	A count of participants who were withdrawn from the study due to meeting stopping criteria. Alert criteria for individual patients with worsening asthma were designed to ensure patient safety. The investigator determined whether the patient's overall clinical picture is consistent with worsening asthma and if the patient should be withdrawn from study drug treatment (but not the study) and be placed on appropriate asthma therapy in the interest of patient safety.; An example of alert criteria is: FEV1 as measured at the study center is below the FEV1 stability limit value calculated at randomization visit (Day 1).; Other criteria as defined in the protocol.	Treatment period: Day 1 up to Week 12
Secondary	Participants With Treatment-Emergent Adverse Events (TEAEs)	An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an inability to carry out usual activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent 1 of the outcomes listed in this definition.	Day 1 up to Week 12
Secondary	Participants With Potentially Clinically Relevant Abnormal Vital Sign Results During the Treatment Period	Criteria for the select vital signs that showed a potentially clinically relevant abnormal result are: Sitting systolic BP (low); <=90 mm Hg and decrease of >=20 mm Hg from baseline; Sitting diastolic BP (high): >=105 mm Hg and increase of >=15 mm Hg from baseline; Baseline is defined as the last available assessment prior to the first dose of double-blind study treatment (usually Day 1 predose).	Baseline (Day 1 predose), Visits at weeks 2, 4, 8, 12
Secondary	Participants With Findings During Oropharyngeal Examination During Treatment	Oropharyngeal examinations were performed at every visit by a qualified healthcare professional: during treatment visits are summarized. Any visual evidence of oral candidiasis during the treatment period of the study was evaluated by obtaining and analyzing a swab of the suspect area for culturing. Appropriate therapy was to be initiated immediately at the discretion of the investigator and was not to be delayed for culture confirmation.	Visits at weeks 2, 4, 8, 12